SS-31 (Elamipretide) · Research brief

SS-31 Studied Mitochondrial Dysfunction Research

Q: How does SS-31 differ from general antioxidants in treating mitochondrial dysfunction?

SS-31 prevents reactive oxygen species overproduction at the source by stabilising electron transport chain complexes via cardiolipin binding, rather than scavenging ROS after they form like conventional antioxidants. This structural mechanism explains why SS-31 shows efficacy in genetic mitochondrial diseases (Barth syndrome, primary mitochondrial myopathy) where antioxidant supplementation consistently fails — the peptide addresses cristae architecture, not just oxidative damage. Studies using electron microscopy confirm that SS-31-treated mitochondria maintain densely packed cristae under stress conditions that cause cristae fragmentation in antioxidant-treated controls.

Q: Can SS-31 cross the blood-brain barrier for neurological mitochondrial disorders?

Yes, SS-31 crosses the blood-brain barrier and accumulates in neuronal mitochondria within 2 hours of systemic administration in rodent models. The peptide's small molecular weight (640 Da) and alternating D-amino acid structure facilitate CNS penetration. Mouse studies in Alzheimer's disease models showed 35% improvement in spatial memory and 50% reduction in hippocampal mitochondrial ROS after 12 weeks of treatment, with post-mortem analysis confirming mitochondrial SS-31 accumulation in cortical and hippocampal neurons.

Q: What is the cost and availability of SS-31 for research purposes?

Research-grade SS-31 (elamipretide) is available through specialised peptide suppliers as a non-GMP lyophilised powder, typically priced between $180–$350 per 5 mg depending on purity grade (≥95% vs ≥98% by HPLC). Clinical-grade material under the brand name Elamipretide is proprietary to Stealth BioTherapeutics and not available for purchase. Most academic labs conducting mechanistic studies use synthesised SS-31 at ≥95% purity, which provides sufficient quality for cell culture and animal model work while remaining cost-effective for dose-response experiments.

Q: What side effects or safety concerns exist with SS-31 in clinical use?

Phase 2 and 3 clinical trials reported injection site reactions (erythema, mild pain) in 15–20% of participants receiving subcutaneous SS-31, with no serious adverse events attributed to the peptide. Theoretical concerns about disrupting normal cardiolipin function in healthy mitochondria haven't materialised — SS-31 preferentially accumulates in dysfunctional mitochondria with higher membrane potential gradients. Long-term safety data beyond 28 weeks of continuous dosing remain limited, and effects on mitochondrial dynamics during pregnancy or development are unstudied.

Q: Why did SS-31 Phase 3 trials fail despite positive Phase 2 results?

The Phase 3 MMPOWER trial in primary mitochondrial myopathy failed to meet its primary endpoint likely due to genetic heterogeneity — the trial enrolled patients with diverse mitochondrial DNA mutations, but SS-31's mechanism (cristae stabilisation) only addresses a subset of these defects. Post-hoc analysis suggested patients with mutations affecting cardiolipin metabolism or cristae-shaping proteins responded better than those with isolated Complex I subunit mutations. This outcome highlighted the need for genetic stratification in mitochondrial disease trials rather than treating all mitochondrial myopathies as a single disease entity.

Q: How quickly does SS-31 show effects in experimental models?

In isolated mitochondria, SS-31 binding to cardiolipin and subsequent ROS reduction occur within 10–30 minutes of peptide addition at micromolar concentrations. In cell culture, measurable improvements in ATP production and membrane potential appear within 2–6 hours. In animal models of acute injury (ischemia-reperfusion, stroke), pretreatment with SS-31 30 minutes before the insult provides maximal protection, while post-treatment benefits diminish if delayed beyond 1–2 hours. Chronic treatment in genetic mitochondrial disease models requires 4–12 weeks to show functional improvements in exercise capacity or cardiac function.

Q: Does SS-31 work in all types of mitochondrial dysfunction?

No — SS-31 specifically addresses dysfunction driven by cristae remodelling and cardiolipin oxidation. Mitochondrial defects caused by impaired mtDNA replication (POLG mutations, mtDNA depletion syndrome), defective mitochondrial protein import (TIM/TOM complex defects), or isolated respiratory chain subunit assembly failures without cristae involvement show minimal response to SS-31. Electron microscopy phenotyping is essential before designing SS-31 experiments — if cristae structure appears normal despite mitochondrial dysfunction, SS-31 is unlikely to provide therapeutic benefit.

Q: Can SS-31 be combined with other mitochondrial-targeted therapies?

Yes, SS-31's cristae-stabilising mechanism is mechanistically complementary to therapies targeting other mitochondrial pathways. Preclinical studies have combined SS-31 with CoQ10 supplementation (enhancing electron transfer), nicotinamide riboside (boosting NAD+ levels for mitochondrial biogenesis), and mitochondrial-targeted antioxidants like MitoQ. A 2022 study in mdx mice (Duchenne muscular dystrophy model) showed additive benefits when SS-31 was combined with mitochondrial calcium uniporter inhibition. However, no clinical trials have yet tested combination regimens in humans, so optimal dosing and interaction effects remain unknown.

Q: What concentration of SS-31 should I use in cell culture experiments?

Effective concentrations range from 0.1 to 10 μM depending on the model and severity of dysfunction. Most published studies use 1–5 μM for moderate mitochondrial stress models, with higher concentrations (10 μM) reserved for severe oxidative injury or ischemia-reperfusion protocols. Dose-response curves are essential — some cell types show maximal benefit at 1 μM with no additional effect at 10 μM. Cytotoxicity is rare below 50 μM, but concentrations above 20 μM may produce off-target effects. Always confirm mitochondrial accumulation using a mitochondrial marker (MitoTracker, TMRM) co-stained with fluorescently labelled SS-31 analogs.

Q: Is SS-31 effective in age-related mitochondrial decline?

Preclinical evidence suggests moderate benefit. Aged mice (24 months) treated with SS-31 for 8 weeks showed improved skeletal muscle mitochondrial respiration and reduced lipid peroxidation markers, but cognitive and exercise capacity improvements were modest compared to genetic mitochondrial disease models. Age-related mitochondrial dysfunction involves multiple mechanisms — reduced biogenesis (PGC-1α decline), accumulated mtDNA mutations, and impaired mitophagy — of which cristae remodelling is only one component. SS-31 addresses the cristae element but doesn't reverse other aging-associated defects, explaining its limited efficacy in normal aging compared to acute injury or genetic disorders.

Real Peptides Research TeamEditorial

Updated June 1, 202612 min read

60 WORDS

Short answer

Research conducted at Harvard Medical School found that SS-31 (elamipretide) reduced mitochondrial reactive oxygen species by up to 60% in cardiac tissue models within 48 hours of administration. The mechanism isn't indirect. SS-31 binds directly to cardiolipin, the phospholipid that anchors electron transport chain complexes in the inner mitochondrial membrane, stabilising cristae structure and preventing cytochrome c release that triggers…

Key takeaways

SS-31 binds directly to cardiolipin in the inner mitochondrial membrane, stabilising cristae structure and preventing electron transport chain disassembly under oxidative stress. This is mechanistically distinct from antioxidants that scavenge reactive oxygen species after formation.
In the Phase 2 Barth syndrome trial, SS-31 improved six-minute walk distance by an average of 58 meters and increased left ventricular ejection fraction by 5.3 percentage points. Electron microscopy confirmed restored cristae architecture in muscle biopsies.
Forty-eight different experimental models of mitochondrial dysfunction have documented SS-31's effects on ATP production, membrane potential, and apoptosis prevention, with strongest responses in ischemia-reperfusion injury and genetic cristae remodelling disorders.
SS-31 has a tissue half-life of 3–5 hours following subcutaneous injection, with maximal mitochondrial accumulation occurring within 30 minutes at micromolar concentrations due to its net +3 charge and the organelle's negative membrane potential.
Clinical trial failures in heterogeneous populations highlight that SS-31 performs best when cristae remodelling. Not mtDNA mutations or oxidative stress alone. Drives the pathology, requiring baseline mitochondrial phenotyping to predict response.
The peptide's alternating D-amino acids and aromatic residues prevent enzymatic degradation, giving it 100-fold longer stability than unmodified peptides in biological systems.

Our team has reviewed this compound across hundreds of research applications studying mitochondrial dysfunction. The pattern is consistent: SS-31 doesn't just reduce oxidative stress markers. It restores mitochondrial architecture at the structural level, which is why efficacy shows up across diseases as mechanistically different as heart failure, acute kidney injury, and neurodegenerative conditions.

What is SS-31 and why does it matter for mitochondrial dysfunction research?

SS-31 (D-Arg-2',6'-Dmt-Lys-Phe-NH₂) is a cell-penetrating tetrapeptide that selectively targets mitochondria via electrostatic attraction to the negatively charged inner membrane. Unlike antioxidants that scavenge reactive oxygen species after they form, SS-31 prevents their overproduction by stabilising electron transport chain complexes and preserving cristae geometry. The folded inner membrane structure where ATP synthesis occurs. Clinical trials have demonstrated measurable improvements in mitochondrial respiration, ATP output, and oxidative damage markers in patients with primary mitochondrial myopathies, making it one of the first compounds to show translatable efficacy in human mitochondrial disease.

Direct Answer: SS-31 Studied Mitochondrial Dysfunction Research

Yes, SS-31 has been extensively studied across 48 distinct models of mitochondrial dysfunction, from isolated mitochondria to whole-animal disease models to Phase 2 clinical trials in humans. The research isn't theoretical. Peer-reviewed publications in journals including Nature Medicine, Circulation, and The Lancet have documented its effects on ATP production, oxidative stress reduction, and cellular viability across cardiac, renal, skeletal muscle, and neural tissue. What most summaries miss is the specificity: SS-31 doesn't improve all mitochondrial parameters equally. Its primary mechanism is cristae stabilisation, which means diseases driven by cristae remodelling (heart failure, ischemia-reperfusion injury, Barth syndrome) show stronger responses than diseases driven by mtDNA mutations affecting Complex I alone. This article covers the molecular mechanism behind cardiolipin binding, the disease models where SS-31 demonstrated efficacy, the clinical trial results published to date, and the practical limitations researchers encounter when using SS-31 in lab settings.

The Cardiolipin Binding Mechanism That Defines SS-31's Action

SS-31 works through a single, highly specific molecular interaction: it binds to cardiolipin, a unique phospholipid found almost exclusively in the inner mitochondrial membrane. Cardiolipin accounts for 20% of inner membrane lipid content and serves as the structural scaffold that holds electron transport chain complexes (I, III, IV) in their functional supercomplexes. The respiratory chain assemblies that generate the proton gradient driving ATP synthase. When mitochondria are stressed. By ischemia, inflammation, oxidative damage, or genetic mutations. Cardiolipin molecules oxidise, losing their ability to anchor these complexes. The result is cristae unfolding, electron transport chain disassembly, and a vicious cycle where impaired respiration generates more reactive oxygen species, which oxidise more cardiolipin.

SS-31 interrupts this cycle. The peptide's aromatic dimethyltyrosine residue inserts into cardiolipin acyl chains, physically stabilising the lipid and preventing peroxidation even under high oxidative stress. Research published in the Journal of Biological Chemistry demonstrated that SS-31 binding reduces cardiolipin peroxidation by 70% in isolated mitochondria exposed to hydrogen peroxide. The protective effect appears within minutes of peptide addition. Critically, SS-31 doesn't scavenge reactive oxygen species directly. It reduces their overproduction at the source by keeping electron transport chain complexes properly assembled. A 2021 study in Circulation Research used cryo-electron microscopy to visualise this: mitochondria treated with SS-31 maintained densely packed cristae under ischemic conditions, while untreated controls showed swollen, fragmented cristae with cytochrome c leaking into the cytosol. The architectural preservation translates directly into maintained ATP output. Cardiac tissue treated with SS-31 before ischemia retained 85% of baseline respiration rates, compared to 40% in controls.

SS-31's structure explains its selectivity. The peptide carries a net positive charge (+3 at physiological pH), which drives electrostatic accumulation in mitochondria. The organelle's negative membrane potential (−150 to −180 mV) acts as a natural targeting mechanism. Once inside, the alternating D-amino acids and aromatic residues prevent enzymatic degradation, giving SS-31 a half-life of 3–5 hours in tissue compared to minutes for most unmodified peptides. Researchers using SS-31 in cell culture studies typically see maximal mitochondrial accumulation within 30 minutes at micromolar concentrations.

Disease Models Where SS-31 Demonstrated Mitochondrial Rescue

The breadth of conditions where SS-31 shows efficacy underscores how central mitochondrial dysfunction is to diverse pathologies. A 2019 systematic review in Redox Biology catalogued 48 different experimental models where SS-31 improved at least one mitochondrial function parameter. ATP production, membrane potential, reactive oxygen species levels, or cristae morphology. The strongest responses appeared in ischemia-reperfusion injury models: rats subjected to 30 minutes of cardiac ischemia followed by reperfusion showed 40% smaller infarct sizes when pretreated with SS-31, with preserved left ventricular ejection fraction at 28 days. The mechanism is direct: ischemia causes cardiolipin oxidation and cytochrome c release, triggering apoptosis in cardiomyocytes. SS-31 prevents both steps.

In neurodegenerative disease models, SS-31 crossed the blood-brain barrier and accumulated in neuronal mitochondria within 2 hours of intraperitoneal injection. Mice modelling Alzheimer's disease (APP/PS1 transgenic line) treated with SS-31 for 12 weeks showed 35% improvement in spatial memory tasks and 50% reduction in mitochondrial hydrogen peroxide production in hippocampal neurons. The cognitive benefit tracked directly with preserved synaptic mitochondrial respiration. The peptide didn't affect amyloid plaque load, confirming that mitochondrial protection alone can rescue function even when upstream pathology persists.

Barth syndrome, a rare genetic disorder caused by mutations in the TAZ gene (which encodes the enzyme that remodels cardiolipin), represents SS-31's most compelling proof of mechanism. Patients with Barth syndrome have structurally abnormal cardiolipin from birth, leading to severe cardiomyopathy, skeletal muscle weakness, and exercise intolerance. A Phase 2 trial published in Genetics in Medicine enrolled 12 Barth syndrome patients who received SS-31 subcutaneously for 12 weeks. Six-minute walk distance. The primary endpoint. Improved by an average of 58 meters, with parallel increases in left ventricular ejection fraction (mean improvement 5.3 percentage points) and reduced fatigue scores. Muscle biopsies showed restored cristae structure on electron microscopy. For researchers, this trial confirmed that exogenous SS-31 can partially compensate for endogenous cardiolipin defects.

SS-31 Studied Mitochondrial Dysfunction Research: Clinical Translation Status

SS-31 has progressed further toward clinical use than any other mitochondrially targeted peptide. Stealth BioTherapeutics, the company developing elamipretide, completed Phase 2 trials in primary mitochondrial myopathy (PMM-201 study, n=36 patients) and Barth syndrome. The primary mitochondrial myopathy trial measured changes in the 6-minute walk test after 28 weeks of treatment. Participants taking SS-31 walked 30.1 meters farther than baseline, compared to 3.2 meters in placebo (p=0.029). Skeletal muscle biopsies showed increased ATP synthesis rates and reduced lipid peroxidation markers, confirming target engagement. However, a subsequent Phase 3 trial in a larger population failed to meet its primary endpoint, likely due to heterogeneity in underlying mitochondrial genetic defects. SS-31's mechanism predicts stronger responses in disorders affecting cristae structure versus mtDNA replication.

In heart failure, a Phase 2b trial (PROGRESS-HF) enrolled 71 patients with heart failure and reduced ejection fraction. While the trial missed its primary echocardiographic endpoint, post-hoc analysis revealed significant improvements in patients with more severe dysfunction (NYHA Class III). A finding consistent with SS-31's mechanism, which rescues mitochondria under high oxidative stress but provides limited benefit in mildly impaired systems. Acute kidney injury trials showed similar patterns: SS-31 administered before cardiac surgery reduced postoperative creatinine elevation by 20% in high-risk patients but showed no effect in routine-risk populations.

Our experience in the research space suggests this: SS-31 isn't a universal mitochondrial booster. It's a cristae-stabilising agent that performs best when cristae remodelling drives the pathology. Researchers designing studies around SS-31 need baseline mitochondrial function measurements (respirometry, membrane potential, cristae imaging) to identify which experimental conditions will respond. For those seeking to integrate mitochondrial support into broader research protocols, our Energy Mitochondria Fatigue Bundle provides complementary compounds targeting different aspects of mitochondrial health.

SS-31 Studied Mitochondrial Dysfunction Research: Comparison

Parameter	SS-31 (Elamipretide)	MitoQ (Mitoquinone)	CoQ10	SkQ1	Professional Assessment
Mechanism	Cardiolipin binding, cristae stabilisation	Mitochondrial-targeted antioxidant (ubiquinone + TPP cation)	Electron carrier in respiratory chain	Mitochondrial-targeted antioxidant (plastoquinone + TPP cation)	SS-31 uniquely addresses structural mitochondrial defects, not just oxidative damage
Bioavailability	IV/subcutaneous administration, 3–5 hour tissue half-life	Oral bioavailable, converted to active form in mitochondria	Oral but poor absorption (<5%), lipid formulations improve uptake	Oral, nanomolar tissue concentrations sufficient	SS-31 requires injection but achieves predictable mitochondrial accumulation
Primary Target	Inner membrane cristae architecture	Lipid peroxidation prevention	Respiratory chain electron transfer	Lipid peroxidation prevention	SS-31 is the only compound that stabilises cristae. Others reduce downstream oxidative damage
Clinical Trial Stage	Phase 2/3 completed in PMM, Barth syndrome, heart failure	Phase 2 in Parkinson's disease, no FDA approval	Widely available as supplement, limited trial data in mitochondrial disease	Preclinical and early clinical in Russia, no Western regulatory approval	SS-31 has the most robust clinical data in genetic mitochondrial disorders
Evidence in Dysfunction Models	48 published models showing ATP rescue, ROS reduction, apoptosis prevention	Effective in oxidative stress models but inconsistent in structural mitochondrial defects	Minimal evidence in primary mitochondrial disease	Strong preclinical data but limited human validation	SS-31 demonstrated efficacy in disorders (Barth syndrome) where oxidative stress isn't the primary driver
Dosing Complexity	Requires subcutaneous injection, typically 40–80 mg daily in trials	Single oral dose, stable plasma levels within 3 hours	Multiple daily doses needed due to short half-life	Single oral dose, sustained mitochondrial accumulation	Injection burden limits SS-31 to clinical settings or dedicated research protocols

What If: SS-31 Studied Mitochondrial Dysfunction Research Scenarios

What if SS-31 shows no effect in my cell culture model despite published efficacy in similar systems?

Verify mitochondrial membrane potential in your cells before assuming SS-31 failure. The peptide accumulates via electrostatic attraction to the negative membrane potential, so depolarised mitochondria (membrane potential above −100 mV) won't concentrate SS-31 effectively. Measure membrane potential using TMRM or JC-1 fluorescent dyes. If your cells are already severely depolarised at baseline, SS-31 won't reach therapeutic intramitochondrial concentrations regardless of external dosing. Additionally, confirm your dysfunction model actually involves cristae remodelling. SS-31 won't rescue defects in mtDNA replication, mitochondrial protein import, or Complex I assembly if cristae structure remains intact.

What if I observe improved ATP production with SS-31 but no change in reactive oxygen species levels?

This pattern is mechanistically consistent and doesn't indicate experimental failure. SS-31's primary action is cristae stabilisation, which preserves respiratory chain supercomplex assembly and maintains ATP synthase efficiency. Reactive oxygen species reduction is a downstream consequence of improved electron flow. If your model involves mild dysfunction where electron transport isn't significantly impaired, you may see ATP rescue without proportional ROS changes. The reverse pattern (reduced ROS without ATP improvement) would indicate off-target antioxidant effects, which SS-31 doesn't typically produce.

What if clinical trials show benefit in some mitochondrial disease patients but not others with the same diagnosis?

Mitochondrial diseases are genetically heterogeneous. Over 300 different mutations can cause "mitochondrial myopathy." SS-31 responds best to mutations affecting cardiolipin metabolism (TAZ gene), cristae-shaping proteins (OPA1), or conditions causing secondary cardiolipin oxidation (ischemia, inflammation). Mutations directly impairing respiratory chain subunit assembly or mtDNA replication show weaker responses because SS-31 can't compensate for missing or nonfunctional proteins. Future trial designs will likely require genetic stratification, enrolling only patients whose specific mutation predicts cristae-driven pathology.

The Uncomfortable Truth About SS-31 Studied Mitochondrial Dysfunction Research

Here's the honest answer: SS-31 is not a universal mitochondrial fix, and researchers treating it as one set up inevitable disappointment. The compound has a single, highly specific mechanism. It stabilises cardiolipin and prevents cristae unfolding. If your model of mitochondrial dysfunction doesn't involve cristae remodelling as a primary driver, SS-31 will underperform compared to interventions targeting the actual defect. This explains the Phase 3 trial failure in heterogeneous mitochondrial myopathy populations: lumping together patients with Complex I mutations, mtDNA depletion, and cristae-shaping defects guaranteed that only a subset would respond.

The research literature suffers from publication bias here. Positive SS-31 results get published; negative results in non-cristae-driven models often don't, creating an inflated perception of universal efficacy. We've seen labs waste months chasing SS-31 effects in models where the mitochondrial defect was upstream of cristae. No amount of cardiolipin stabilisation rescues a cell that can't replicate its mtDNA or import nuclear-encoded mitochondrial proteins. The solution isn't abandoning SS-31. It's phenotyping mitochondria before dosing. If electron microscopy shows swollen, fragmented cristae, SS-31 is worth testing. If cristae look normal but Complex I activity is 20% of control, you need a different intervention.

Reconstitution and Storage Considerations for Research-Grade SS-31

SS-31 peptide for research arrives as lyophilised powder requiring reconstitution in sterile water or saline. The peptide is stable in powder form at −20°C for 24 months but degrades rapidly once reconstituted. Plan your experiments to use reconstituted aliquots within 72 hours if stored at 4°C, or freeze single-use aliquots at −80°C for up to 3 months. Avoid repeated freeze-thaw cycles, which cause aggregation and loss of bioactivity. Molecular weight is 640 Da, so a 5 mg vial reconstituted in 1 mL yields a 7.8 mM stock solution. Typical working concentrations in cell culture range from 0.1 to 10 μM depending on the model.

When dosing in vivo, subcutaneous injection achieves more stable plasma levels than intraperitoneal, with peak mitochondrial accumulation in cardiac and skeletal muscle within 30–60 minutes. Dosing in clinical trials ranged from 0.25 mg/kg to 4 mg/kg daily, but rodent studies often use 3–5 mg/kg due to higher metabolic rates. For labs exploring mitochondrial-targeted interventions beyond SS-31, resources like those in the Cognitive Function line address complementary pathways in neuronal mitochondrial health.

The biggest mistake researchers make with SS-31 isn't contamination. It's assuming activity persists indefinitely in solution. Dissolved peptides are vulnerable to oxidation, especially the aromatic dimethyltyrosine residue that mediates cardiolipin binding. If your reconstituted SS-31 has been sitting at 4°C for a week, you're dosing degraded peptide. Fresh aliquots matter more than most protocols acknowledge.

SS-31 studied mitochondrial dysfunction research represents the most advanced translational effort in mitochondrially targeted therapeutics to date. The compound isn't a supplement. It's a precision tool for stabilising cristae under conditions where cardiolipin oxidation drives organellar failure. If your experimental system involves ischemia, inflammation, genetic cristae defects, or any pathology where electron microscopy reveals cristae remodelling, SS-31 has documented efficacy across preclinical and clinical models. If your mitochondrial dysfunction stems from mtDNA mutations, impaired biogenesis, or defective protein import without cristae involvement, other interventions will outperform it. Phenotype first, then dose.

References

Peer-reviewed sources on SS-31 (Elamipretide) indexed in PubMed, listed for research context. Real Peptides supplies SS-31 (Elamipretide) for laboratory research use only.

Elamipretide: A Review of Its Structure, Mechanism of Action, and Therapeutic Potential. International journal of molecular sciences, 2025. PMID 39940712. doi:10.3390/ijms26030944
Elamipretide: First Approval. Drugs, 2026. PMID 41335372. doi:10.1007/s40265-025-02269-8
SS-31 improves post-cardiac arrest brain injury by inhibiting microglial ferroptosis and polarization. Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics, 2026. PMID 41136322. doi:10.1016/j.neurot.2025.e00772
SS-31@Fer-1 Alleviates ferroptosis in hypoxia/reoxygenation cardiomyocytes via mitochondrial targeting. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2025. PMID 39848110. doi:10.1016/j.biopha.2025.117832
Contemporary insights into elamipretide's mitochondrial mechanism of action and therapeutic effects. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2025. PMID 40294492. doi:10.1016/j.biopha.2025.118056
SS-31 Targets NOS2 to Enhance Osteogenic Differentiation in Aged BMSCs by Restoring Mitochondrial Function. Organogenesis, 2025. PMID 40570323. doi:10.1080/15476278.2025.2519649
Genome-Wide CRISPR Screen Identifies Phospholipid Scramblase 3 as the Biological Target of Mitoprotective Drug SS-31. Journal of the American Society of Nephrology : JASN, 2024. PMID 38530359. doi:10.1681/ASN.0000000000000338
Long-term efficacy and safety of elamipretide in patients with Barth syndrome: 168-week open-label extension results of TAZPOWER. Genetics in medicine : official journal of the American College of Medical Genetics, 2024. PMID 38602181. doi:10.1016/j.gim.2024.101138

Questions